Tag: LDE225

It is assumed that an effective human immunodeficiency virus type 1 (HIV-1) vaccine should be capable of eliciting neutralizing antibodies. HIV-1 variations per subtype (A, B, D) and C. Solid cross-clade neutralizing activity was recognized in sera from seven people. Strikingly, sera from 22 of 35 people (63?%) neutralized three or even more from the…